Pyros Pharmaceuticals’ Abstract Accepted for Poster Presentation at the American Epilepsy Society (AES) 2024 Annual Meeting

PARSIPPANY, N.J.--(BUSINESS WIRE)--Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, today details an abstract accepted for poster presentation at the American Epilepsy Society (AES) 2024 Annual Meeting, December 6-10, 2024, in Los Angeles.

Details of the AES poster presentation:

Title: Comparison of Vigabatrin Oral Solution Versus SABRIL^® Powder for Oral Solution in Infantile Spasms by Caregivers

Poster Number: 2.398

Date and Time: Poster Session 2, Sunday, December 8, 2024

Location: Los Angeles Convention Center, South Lobby, Street Level, South Hall H, Level 1

Summary: This poster will provide results from a study that compared the ability of study participants, comprised of caregivers and non-caregivers, to accurately provide a single dose of vigabatrin using both Vigabatrin Oral Solution and SABRIL^® Powder for Oral Solution.

About Pyros

Pyros Pharmaceuticals is developing enhanced specialty pharmaceuticals for rare diseases. Our mission is to elevate the standard of care for infantile spasms, providing treatment options that significantly improve the lives of affected children. Through our enhanced therapies and comprehensive support services, we aim to assist providers and caregivers in navigating the complexities of the patient journey.

For more information, please visit: www.pyrospharma.com

Forward-Looking Statements

The Company has made statements throughout this press release which constitute forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause its actual results, levels of activity, performance or achievements to be materially different from any results, levels of activity, performance or achievements expressed or implied by any such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expect,” “hopes,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “likely,” “potential,” or “continue” or the negative of these terms and similar words. Although management believe that the expectations reflected in these forward-looking statements are reasonable, management cannot guarantee future results, levels of activity, performance or achievements. Furthermore, management undertakes no obligation to update any forward-looking statements for any reason unless required to do so by law.

*SABRIL^® is a registered trademark of Lundbeck.